Enoxaparin prophylaxis in elective hip surgery.

Abstract

A randomized double-blind placebo-controlled trial to determine the efficacy and safety of enoxaparin for the prevention of deep vein thrombosis in patients undergoing elective hip surgery was performed. Prophylaxis, with enoxaparin in a dose of 30 mg subcutaneously twice daily, was begun post-operatively and continued for 14 days. Deep vein thrombosis occurred in 6 (12%) of 50 patients in the enoxaparin group and 21 (42%) of 50 patients in the placebo group (p = 0.0007). Proximal vein thrombosis occurred in two (4%) of the enoxaparin group and 10 (20%) of the placebo group (p = 0.014). Two patients in the placebo group and two in the enoxaparin group developed haemorrhagic complications. This study indicates that fixed-dose enoxaparin begun post-operatively is effective and safe for the prevention of deep vein thrombosis in patients undergoing elective hip replacement.

• Authors: A G Turpie
• Journal: Acta chirurgica Scandinavica. Supplementum (Acta Chir Scand Suppl) Vol. 556 Pg. 103-7 ( 1990) ISSN: 0301-1860 [Print] Sweden
• PMID: 1963014 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Heparin, Low-Molecular-Weight
• Placebos

Topics

• Aged
• Double-Blind Method
• Female
• Heparin, Low-Molecular-Weight (administration & dosage, therapeutic use)
• Hip Prosthesis (adverse effects)
• Humans
• Incidence
• Injections, Subcutaneous
• Male
• Ontario (epidemiology)
• Placebos
• Plethysmography, Impedance
• Postoperative Complications (epidemiology, prevention & control)
• Thrombophlebitis (epidemiology, prevention & control)